FOR PATIENTS & CAREGIVERS
Study enrollment
All potential treatments must go through clinical studies (also known as clinical trials) before being approved. These carefully designed studies require volunteers who are willing to participate and potentially gain access to cutting-edge therapies. Those who participate in a clinical study are contributing to research and play a crucial role in bringing innovative treatments to patients in need. General information about clinical studies can be found here: National Institutes of Health (NIH).
At A2 Bio, we understand that enrolling into a clinical study can feel overwhelming for patients. That is why we have ensured our enrollment and study processes are as clear and straightforward as possible for both patients and investigators.
BASECAMP-1
Patient perspective: what to expect
Explore the patient journey diagram and watch the video below to understand the steps involved.
Patient journey during BASECAMP-1
Eligible patients who decide to participate in our pre-screening study, BASECAMP-1, will undergo a series of tests and procedures.
Understanding BASECAMP-1
Watch this video to discover the vital role of clinical trials and to understand what patients can expect if they are eligible to join the BASECAMP-1 study.
Participating in BASECAMP-1
If you are interested in participating in BASECAMP-1, we encourage you to speak with your healthcare provider first about what is involved and your eligibility.
To discuss enrolling into BASECAMP-1, or if you would like more information, please contact us: clinicaltrials@a2bio.com or (310) 431-9180.
Important terms:
Apheresis (leukapheresis): a procedure where blood is removed from your vein, the white blood cells are separated in a machine, and the rest of the blood is returned to your body
CAR T-cell therapy: this therapy works by obtaining T cells from your blood, then introducing a gene into those cells that allows them to recognize and attack cancer cells after they are returned to the body
Heterozygous: all genes come in pairs, 1 from your mother and 1 from your father. A gene is heterozygous when the gene from your mother is different from the gene from your father
HLA-A*02: a specific type of human leukocyte antigen (HLA) and the most common type in North America. Approximately one third of people are HLA-A*02 heterozygous
Human leukocyte antigen (HLA): a group of proteins that are important for the immune system to recognize and distinguish between the body’s own cells and foreign cells
Loss of heterozygosity (LOH): occurs when your tumor loses some genetic material you were born with
Observational study: a study where no treatment is administered
T cells: a type of white blood cell, which helps fight infection
Current studies
Explore additional information on our ongoing clinical studies that are recruiting patients.
Pre-screening study
BASECAMP-1
Aims to find patients who might be suitable for treatment with an investigational therapy in one of our clinical studies. For adults with mesothelioma or colorectal, non-small cell lung, pancreatic, or ovarian cancers; or other solid tumors that have lost HLA-A*02 expression.
Interventional studies
EVEREST-1
Aims to understand the safety and efficacy of an investigational TmodTM CAR T-cell therapy (A2B530) in germline heterozygous HLA-A*02 adults with colorectal, non-small cell lung, or pancreatic cancers, or other solid tumors that express the biomarker CEA and have lost HLA-A*02 expression.
EVEREST-2
Aims to understand the safety and efficacy of an investigational TmodTM CAR T-cell therapy (A2B694) in germline heterozygous HLA-A*02 adults with mesothelioma, or colorectal, non-small cell lung, pancreatic, or ovarian cancers; or other solid tumors that express the biomarker MSLN and have lost HLA-A*02 expression.
Abbreviations
CAR, chimeric antigen receptor; CEA, carcinoembryonic antigen; HLA, human leukocyte antigen; LOH, loss of heterozygosity; MSLN, mesothelin; NIH, National Institutes of Health.